Washington Report - Pharmaceutical Executive

ADVERTISEMENT

Washington Report
News stories on health policy developments from the Hill and their effect on the pharmaceutical industry

Pre-emption and States' Rights

July 23, 2014

Pharma backs federal standards for compassionate use, drug importing, data transparency, and track-and-trace. Jill Wechsler reports.

What Price Innovation?

June 16, 2014

Payers are seeking clear assessment of drug value to rationalize high drug prices. This issue has moved to center stage due to mounting concern over the high price for Gilead's Sovaldi, writes Jill Wechsler.

Reimbursement Limits Threaten Drug Access

May 22, 2014

Despite provisions in the Affordable Care Act that require qualified health plans to cover 'basic' benefits, access to prescription drugs may be limited by high out-of-pocket costs and tight pharmacy management strategies.

Obama Policies Reshape Pharma Marketing

April 10, 2014

Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler.

Data disclosure, integrity challenge pharma

March 1, 2014

Transparency initiatives are multiplying, affecting research, marketing and compliance.

Drug Coverage, Costs Under Scrutiny

February 1, 2014

Benefits offered by insurance plans on health exchanges and through Medicare are raising concerns about patient access to needed therapies, writes Jill Wechsler.

Pharma Challenges for 2014

January 1, 2014

Pricing and personalized medicine are key themes shaping drug development and marketing

FDA Pursues Delicate Balancing Act

December 1, 2013

The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.

Transparency Troubles for Pharma

November 1, 2013

High prices, murky financial relations, and a reluctance to disclose clinical data undermine public trust in industry and the research enterprise.

ADVERTISEMENT

Click here